Newsroom

MEDIA

BIOCENTURY

February 10, 2026

Galux: Scaling AI-designed biologics

Read More

MEDIA

BIOWORLD

February 10, 2026

AI meets antibody design: Galux draws $29M series B for drug R&D

Read More

NEWS

February 10, 2026

Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery

Read More

NEWS

February 9, 2026

ISU Abxis and Galux Launch AI-Driven Collaboration to Develop Next-Generation Therapies for Rare Diseases

Read More

MEDIA

FIRSTWORD PHARMA

December 18, 2025

For its next AI deal, Boehringer turns to Galux for precision protein design

Read More

NEWS

December 17, 2025

Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design

Read More

NEWS

December 11, 2025

Galux and Seoul National University Develop ‘T-SCAPE,’ an AI for Predicting Immunogenicity of Drug Candidates

Read More

NEWS

December 2, 2025

Galux and Celltrion Enter Strategic Partnership to Co-Develop Next-Generation Multispecific Antibodies for Autoimmune Diseases

Read More

INTERVIEW

THE BIO

December 1, 2025

Galux claims ‘one-day antibody design’ as it enters the global top-three AI race

Read More

NEWS

November 26, 2025

Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design

Read More

NEWS

November 14, 2025

Galux and ISU Abxis Sign MOU to Collaborate on AI-Driven Drug Discovery

Read More

NEWS

September 30, 2025

Galux and Woojung Bio Forge Strategic Partnership to Accelerate AI-Driven Therapeutics Development

Read More